Front Row Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12.3K | Hold |
221
| – | – | ﹤0.01% | 363 |
|
|
2025
Q4 | $10.9K | Hold |
221
| – | – | ﹤0.01% | 369 |
|
|
2025
Q3 | $9.63K | Hold |
221
| – | – | ﹤0.01% | 387 |
|
|
2025
Q2 | $8.67K | Buy |
221
+61
| +38% | +$2.33K | ﹤0.01% | 386 |
|
|
2025
Q1 | $6.26K | Hold |
160
| – | – | ﹤0.01% | 401 |
|
|
2024
Q4 | $5.41K | Hold |
160
| – | – | ﹤0.01% | 402 |
|
|
2024
Q3 | $6.6K | Sell |
160
-200
| -56% | -$8.18K | ﹤0.01% | 392 |
|
|
2024
Q2 | $14K | Hold |
360
| – | – | ﹤0.01% | 496 |
|
|
2024
Q1 | $15.5K | Buy |
360
+200
| +125% | +$8.25K | 0.01% | 475 |
|
|
2023
Q4 | $5.99K | Hold |
160
| – | – | ﹤0.01% | 364 |
|
|
2023
Q3 | $5.86K | Hold |
160
| – | – | ﹤0.01% | 635 |
|
|
2023
Q2 | $6K | Hold |
160
| – | – | ﹤0.01% | 632 |
|
|
2023
Q1 | $6K | Hold |
160
| – | – | ﹤0.01% | 635 |
|
|
2022
Q4 | $6K | Hold |
160
| – | – | ﹤0.01% | 606 |
|
|
2022
Q3 | $5K | Sell |
160
-260
| -62% | -$9.85K | ﹤0.01% | 650 |
|
|
2022
Q2 | $23K | Sell |
420
-7
| -2% | -$386 | 0.01% | 357 |
|
|
2022
Q1 | $24K | Sell |
427
-13
| -3% | -$706 | 0.01% | 373 |
|
|
2021
Q4 | $25K | Hold |
440
| – | – | 0.01% | 380 |
|
|
2021
Q3 | $21K | Hold |
440
| – | – | 0.01% | 407 |
|
|
2021
Q2 | $23K | Buy |
440
+280
| +175% | +$13.5K | 0.01% | 392 |
|
|
2021
Q1 | $7K | Sell |
160
-166
| -51% | -$7.54K | ﹤0.01% | 635 |
|
|
2020
Q4 | $15K | Sell |
326
-6
| -2% | -$276 | 0.01% | 432 |
|
|
2020
Q3 | $15K | Buy |
332
+78
| +31% | +$3.91K | 0.01% | 424 |
|
|
2020
Q2 | $13K | Hold |
254
| – | – | 0.01% | 416 |
|
|
2020
Q1 | $13K | Buy |
254
+140
| +123% | +$7.47K | 0.01% | 409 |
|
|
2019
Q4 | $7K | Buy |
+114
| New | +$6.34K | ﹤0.01% | 541 |
|
|
2019
Q2 | – | Sell |
-48
| Closed | -$3K | – | 1051 |
|
|
2019
Q1 | $3K | Hold |
48
| – | – | ﹤0.01% | 732 |
|
|
2018
Q4 | $2K | Hold |
48
| – | – | ﹤0.01% | 782 |
|
|
2018
Q3 | $2 | Sell |
48
-157
| -77% | -$7.98K | ﹤0.01% | 788 |
|
|
2018
Q2 | $11 | Sell |
205
-1
| -0.5% | -$50 | 0.01% | 435 |
|
|
2018
Q1 | $10K | Sell |
206
-3
| -1% | -$140 | 0.01% | 436 |
|
|
2017
Q4 | $9K | Buy |
+209
| New | +$9.65K | 0.01% | 447 |
|
Other funds holding GSK
JEST
Front Row Advisors's GSK Position: Q1 2026 in Review
Front Row Advisors held its GSK (GSK) position steady in Q1 2026 at 221 shares worth $12.3K. The position accounts for ﹤0.01% of the portfolio, ranked #363.
Front Row Advisors first reported a position in GSK in Q4 2017 and has held it in 32 quarters since. The position peaked at $25K in Q4 2021. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Front Row Advisors held 221 shares of GSK worth $12.3K as of Q1 2026.
- Front Row Advisors left its GSK share count unchanged in Q1 2026.
- GSK made up ﹤0.01% of Front Row Advisors's portfolio in Q1 2026, its #363 holding.
- Front Row Advisors first reported a position in GSK in Q4 2017 and has held it in 32 quarters since.
- Front Row Advisors's GSK position peaked at $25K in Q4 2021.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Front Row Advisors's 13F filing for Q1 2026, filed 19 May 2026.